Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.
CEO: Richard Jon Barry. Company website
Filana Therapeutics, Inc. (FLNA) trades at $0.73, up 0.83% on the day, as of Sep 20, 2026 14:57 UTC.
Filana Therapeutics, Inc. has a market capitalisation of $35.07M, calculated from the live FLNA share price and shares outstanding.
FLNA has no meaningful price-to-earnings ratio: Filana Therapeutics, Inc. lost $0.87 per share over the last twelve months, and a P/E is only defined on positive earnings.
Filana Therapeutics, Inc. generated revenue of $0.00 over the trailing twelve months.
FLNA has traded between $0.67 and $2.49 over the past 52 weeks, and the last price is 70.8% below that high.
Yes. Filana Therapeutics, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.
Filana Therapeutics, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Richard Jon Barry is the chief executive of Filana Therapeutics, Inc., which employs 19 people.
QFI Terminal shows FLNA with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open FLNA in Terminal See plans